SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 /PRNewswire/ — Enable Biosciences Inc. has shared compelling new data on the performance of its Antibody Detection by Agglutination-PCR (ADAP) technology in accurately predicting the risk of pre-symptomatic Type 1 Diabetes (T1D). Detailed…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.